US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Kits Eyecare Ltd (PK) (KTYCF) 銘柄情報

Kits Eyecare Ltd (PK) (KTYCF)

9.8525

0.3725

(3.93%)

終了 6月8日 5:00AM

Kits Eyecare Ltd (PK) (KTYCF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

9.8525

( 3.93% )

買値

9.75

売値

11.41

出来高

7,005

9.8525 日の範囲 9.8525

7.735 52 週間の範囲 16.38

時価総額

前日終値

9.48

始値

9.8525

時刻

最終取引時間

財務取引量

US$ 69,017

VWAP

9.8525

平均取引量 (3 か月)

US$ 139,053

発行済株式数

33,995,464

配当利回り

PER

132.02

1 株当たり利益 (EPS)

0.1

歳入

213.33M

純利益

3.48M

Kits Eyecare Ltd. operates a digital eyecare platform in the United States and Canada. It offers progressive, polarized, and contact lenses, eyeglasses, and frames under the KITS brand, as well as distributes eyewear products of various brands. The company operates a network of optical e-commerce we... Kits Eyecare Ltd. operates a digital eyecare platform in the United States and Canada. It offers progressive, polarized, and contact lenses, eyeglasses, and frames under the KITS brand, as well as distributes eyewear products of various brands. The company operates a network of optical e-commerce websites, including KITS.com, KITS.ca, OptiContacts.com, and ContactsExpress.ca. Kits Eyecare Ltd. was founded in 2002 and is headquartered in Vancouver, Canada. 詳細を表示

セクター

Consumer Discretionary

業界

Retail - Discretionary

ウェブサイト

www.kits.com

本社

Vancouver, Canada

設立

2026

Kits Eyecare Ltd (PK) is listed in the Consumer Discretionary sector of the その他OTC with ticker KTYCF. The last closing price for Kits Eyecare (PK) was US$9.48. Over the last year, Kits Eyecare (PK) shares have traded in a share price range of US$ 7.735 to US$ 16.38.

Kits Eyecare (PK) currently has 33,995,464 shares in issue. The market capitalisation of Kits Eyecare (PK) is US$334.94 million. Kits Eyecare (PK) has a price to earnings ratio (PE ratio) of 132.02.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.5025	5.3743315508	9.35	10.05	9.32	9117	9.65868726	CS
4	1.4525	17.2916666667	8.4	11.06	7.735	11384	8.49691556	CS
12	-1.0375	-9.52708907254	10.89	11.5	7.735	12483	9.69609695	CS
26	-1.4375	-12.732506643	11.29	16.38	7.735	11387	11.64889379	CS
52	-0.6475	-6.16666666667	10.5	16.38	7.735	7894	11.39531491	CS
156	6.6825	210.804416404	3.17	16.38	3.09	5280	9.71132235	CS
260	3.6525	58.9112903226	6.2	16.38	1.33	5341	7.27479603	CS

KTYCF - Frequently Asked Questions (FAQ)

What is the current Kits Eyecare Ltd (PK) share price?

The current share price of Kits Eyecare Ltd (PK) is US$ 9.8525

How many Kits Eyecare Ltd (PK) shares are in issue?

Kits Eyecare Ltd (PK) has 33,995,464 shares in issue

What is the market cap of Kits Eyecare Ltd (PK)?

The market capitalisation of Kits Eyecare Ltd (PK) is USD 334.94M

What is the 1 year trading range for Kits Eyecare Ltd (PK) share price?

Kits Eyecare Ltd (PK) has traded in the range of US$ 7.735 to US$ 16.38 during the past year

What is the PE ratio of Kits Eyecare Ltd (PK)?

The price to earnings ratio of Kits Eyecare Ltd (PK) is 132.02

What is the cash to sales ratio of Kits Eyecare Ltd (PK)?

The cash to sales ratio of Kits Eyecare Ltd (PK) is 2.11

What is the registered address of Kits Eyecare Ltd (PK)?

The registered address for Kits Eyecare Ltd (PK) is 510 Seymour Street, Vancouver, British Columbia, V6B 3J5

What is the Kits Eyecare Ltd (PK) website address?

The website address for Kits Eyecare Ltd (PK) is www.kits.com

Which industry sector does Kits Eyecare Ltd (PK) operate in?

Kits Eyecare Ltd (PK) operates in the Retail - Discretionary sector

MovedAlong

MovedAlong 6分前

VIVO is doing great.

TexasMarvL

TexasMarvL 9分前

I keep looking at those extremely good drill results from the 904 complex. Very High Grade.

Near term, the 13 level East Drive will open up 350,000 high grade ounces.

What if the company created a 13 Level West Drive to unlock the Upper 8 zone and extended

Seminole Red

Seminole Red 10分前

MONTI KING

MONTI KING 13分前

Great question! By buying this note for only $1000, SB Technology Holdings ($VGLS) instantly changed its legal definitions. The company is now actively engaged in "the acquisition, management, and restructuring of technology-related corporate debt." It doesn't matter if the note is impaired, what ma

rjurko

rjurko 16分前

Jay,

Yes, please feel free to post on X. To clarify, I do not say that vaccines are all misplaced, of course, but rather that they have a proper place in disease treatment when properly developed. AND to place too much reliance on just that treatment modality within the evolving lan

DayofReckoning

DayofReckoning 16分前

They can’t sell and move on.. no bid .. pumping it into oblivion with 30 billion AS 22 billion OS
$GTCH no cash no bid way to go

georgejjl

georgejjl 17分前

Blarcamesine had a proper Phase 2b/3 trial with statistically significant results.

GOD bless,

12yearplan

12yearplan 18分前

Lol, where you from?. The only record is the pump bash matrix. Take a pill.
https://investorshub.advfn.com/boards/msgsearch.aspx?searchstr=wok
$WOK
https://www.youtube.com/watch?v=7YO0clA_U-k

jour_trader

jour_trader 18分前

BMY’s 10-K:
Regarding generic Eliquis launch:
“ Under the terms of previously executed settlement agreements, the generic companies with whom BMS settled are permitted to launch in 2028, subject to additional challenges. ”

gdl

Analyzing the political implosion against an economic calamity I MUST give strong credence to the possibility we are in a countdown for a crash here. I know, my track record and willingness to see gremlins is strong. But the menel state of the investor, AKA top 5%, and the pavlova response every ti

PennyMillions852

PennyMillions852 19分前

OTC scam along with $TWOH, one is no bid, and the other one is garbage that has been at .002 for months now without moving despite the pump tactics!😆😆

JRyan

Some detailed information on the carbonate question

THE HONEST BRIDGE TO ZION

There is a real, defensible connection here, and it is worth stating without inflating it:

- The transect in Figure 3 literally runs ONSHORE into southern Israel. The framework

Genz2

Methinks, I think someone should tell Trump a few good jokes!!! Laughter is the best medicine!!! Well, and of course if he got a dog that would help him with his soul!!! Have you seen his eyes lately?? He doesn’t look happy very often!!! I think laughter and a dog would help him live a lot long

archilles

archilles 23分前

I and many shareholders congratulate VIVO for its achievement so far of submitting the IDE application to the FDA. Best of luck to VIVO and all of us shareholders.

PickStocks

PickStocks 23分前

The only thing JPM is paying through a 3rd party is for the Euro notes/bonds.. these were always guaranteed….the rest….after 17+ years….looks very weak…this unfortunately….but keep posting your numbers….they can only be right if it happens…wait for Cactus to tell you and others dd is wrong except fo

LunarDimension21

LunarDimension21 25分前

wshaw14

wshaw14 25分前

Yes, but my suggestion would be to use the mid point between 35,000 and 45,000 which would be 40,000. If they dont at least come close to my numbers in Q2 I will consider moving some money elsewhere. As of right now I am still adding a little at a time.

40,000 × 40% = 16,000 in 2026-

Eli's Gone

Eli's Gone 25分前

JoJr

I ignored you then gave you a second chance.
You screwed the pooch twice.
Bye Bye

gfp927z

gfp927z 27分前

KRISGO

KRISGO 29分前

I saw the MHRA confirmation email that SemperFi shared. June will be over before we know it, and other than watching the share count continue to increase through dilution, we may not hear much of anything from the company. That's why even small pieces of information or reassurance from someone who h

Kits Eyecare (PK)

abrdn Asiapacific Income

Easterly Government Prop...

Agf Global Equity Fund M...

Vinacapital Vietnam Oppo... (PK)

Rse Archive (GM)

CAC Real Estate

INXTMSUS CONST1C DL

Atlantic Insurance Co Pu...

Aramark International Fi...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。